EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synergy between Interleukin-1β, Interferon-γ, and Glucocorticoids to Induce TLR2 Expression Involves NF-κB, STAT1, and the Glucocorticoid Receptor

Akanksha Bansal, Cora Kooi, Keerthana Kalyanaraman, Sachman Gill, Andrew Thorne, Priyanka Chandramohan, Amandah Necker-Brown, Mahmoud M Mostafa iD, Arya Milani, Richard Leigh, Robert Newton iD

Molecular Pharmacology · 2024

DOI: 10.1124/molpharm.123.000740 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmacology, 2024. Verfasst von Akanksha Bansal und 10 weiteren Autor:innen. Beteiligte Einrichtung: Departments of Physiology and Pharmacology (A.B., K.K., S.G., A.T., P.C., A.N.-B., M.M.M., A.M., R.N.) and Medicine (C.K., R.L.), Lung Health Researc…. Hauptthemen laut MEDLINE: Glucocorticoids, Asthma. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glucocorticoids act via the glucocorticoid receptor (GR; NR3C1) to downregulate inflammatory gene expression and are effective treatments for mild to moderate asthma. However, in severe asthma and virus-induced exacerbations, glucocorticoid therapies are less efficacious, possibly due to reduced repressive ability and/or the increased expression of proinflammatory genes. In human A549 epithelial and primary human bronchial epithelial cells, toll-like receptor (TLR)-2 mRNA and protein were supra-additively induced by interleukin-1β (IL-1β) plus dexamethasone (IL-1β+Dex), interferon-γ (IFN-γ) plus dexamethasone (IFN-γ+Dex), and IL-1β plus IFN-γ plus dexamethasone (IL-1β+IFN-γ+Dex). Indeed, ∼34- to 2100-fold increases were apparent at 24 hours for IL-1β+IFN-γ+Dex, and this was greater than for any single or dual treatment. Using the A549 cell model, TLR2 induction by IL-1β+IFN-γ+Dex was antagonized by Org34517, a competitive GR antagonist. Further, when combined with IL-1β, IFN-γ, or IL-1β+IFN-γ, the enhancements by dexamethasone on TLR2 expression required GR. Likewise, inhibitor of κB kinase 2 inhibitors reduced IL-1β+IFN-γ+Dex-induced TLR2 expression, and TLR2 expression induced by IL-1β+Dex, with or without IFN-γ, required the nuclear factor (NF)-κB subunit, p65. Similarly, signal transducer and activator of transcription (STAT)-1 phosphorylation and γ-interferon-activated sequence-dependent transcription were induced by IFN-γ These, along with IL-1β+IFN-γ+Dex-induced TLR2 expression, were inhibited by Janus kinase (JAK) inhibitors. As IL-1β+IFN-γ+Dex-induced TLR2 expression also required STAT1, this study reveals cooperation between JAK-STAT1, NF-κB, and GR to upregulate TLR2 expression. Since TLR2 agonism elicits inflammatory responses, we propose that synergies involving TLR2 may occur within the cytokine milieu present in the immunopathology of glucocorticoid-resistant disease, and this could promote glucocorticoid resistance. SIGNIFICANCE STATEMENT: This study highlights that in human pulmonary epithelial cells, glucocorticoids, when combined with the inflammatory cytokines interleukin-1β (IL-1β) and interferon-γ (IFN-γ), can synergistically induce the expression of inflammatory genes, such as TLR2. This effect involved positive combinatorial interactions between NF-κB/p65, glucocorticoid receptor, and JAK-STAT1 signaling to synergistically upregulate TLR2 expression. Thus, synergies involving glucocorticoid enhancement of TLR2 expression may occur in the immunopathology of glucocorticoid-resistant inflammatory diseases, including severe asthma.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucocorticoidsAsthmaHumansNF-kappa BInterferon-gammaReceptors, GlucocorticoidInterleukin-1betaToll-Like Receptor 2CytokinesDexamethasoneSTAT1 Transcription Factor

Substanzen

GlucocorticoidsNF-kappa BInterferon-gammaReceptors, GlucocorticoidInterleukin-1betaToll-Like Receptor 2CytokinesDexamethasoneTLR2 protein, humanSTAT1 protein, human

Autor:innen und Institutionen

  • Departments of Physiology and Pharmacology (A.B., K.K., S.G., A.T., P.C., A.N.-B., M.M.M., A.M., R.N.) and Medicine (C.K., R.L.), Lung Health Research Group, Snyder Institute for Chronic Diseases, Cumming School of Medi…

ORCID-Profile: Mahmoud M Mostafa, Robert Newton

Zitieren

APA

Bansal, A., Kooi, C., Kalyanaraman, K., Gill, S., Thorne, A., Chandramohan, P., Necker-Brown, A., Mostafa, M. M., Milani, A., Leigh, R., & Newton, R. (2024). Synergy between Interleukin-1β, Interferon-γ, and Glucocorticoids to Induce TLR2 Expression Involves NF-κB, STAT1, and the Glucocorticoid Receptor. Molecular Pharmacology. https://doi.org/10.1124/molpharm.123.000740

Vancouver

Bansal A, Kooi C, Kalyanaraman K, Gill S, Thorne A, Chandramohan P, et al. Synergy between Interleukin-1β, Interferon-γ, and Glucocorticoids to Induce TLR2 Expression Involves NF-κB, STAT1, and the Glucocorticoid Receptor. Molecular Pharmacology. 2024. doi:10.1124/molpharm.123.000740

BibTeX
@article{Bansal2024,
  author = {Bansal, Akanksha and Kooi, Cora and Kalyanaraman, Keerthana and Gill, Sachman and Thorne, Andrew and Chandramohan, Priyanka and Necker-Brown, Amandah and Mostafa, Mahmoud M and Milani, Arya and Leigh, Richard and Newton, Robert},
  title = {Synergy between Interleukin-1β, Interferon-γ, and Glucocorticoids to Induce TLR2 Expression Involves NF-κB, STAT1, and the Glucocorticoid Receptor},
  journal = {Molecular Pharmacology},
  year = {2024},
  doi = {10.1124/molpharm.123.000740}
}
Kostenlos starten →